Capital Cell

MgShell is a developer of innovative intraocular devices aimed at treating age-related macular degeneration and other ocular diseases. The company has created a biodegradable drug delivery device that effectively replicates existing clinical practices while significantly reducing the frequency of intravitreal injections required for treatment. This technology allows for the autonomous release of therapeutic drug doses at predetermined intervals, minimizing the need for surgical procedures and enhancing patient adherence to therapy. By addressing the therapeutic burdens associated with traditional treatment methods, MgShell's products aim to reduce the risk of vision loss among patients with maculopathy and retinal diseases.

MSInsight bioinformatics start-up that develops diagnostic and treatment response prediction solutions for Microsatellite Instability (MSI) cancers. Its service offering focuses on diagnostic and prognostic biomarkers of treatment response for MSI tumors.

OxyPrem AG is a Swiss company that specializes in developing and manufacturing sensor solutions for monitoring preterm infants. Founded in 2018 and based in Zurich, OxyPrem offers an advanced reusable oxygen sensor that continuously measures brain oxygen levels in high-risk preterm infants using noninvasive near-infrared light technology. This device accurately determines hemoglobin oxygen saturation in any human tissue, allowing healthcare providers to deliver improved clinical care while significantly reducing waste. By enabling real-time monitoring, OxyPrem's technology plays a crucial role in preventing early death and mitigating the risk of severe long-term brain damage in this vulnerable population.

Affirma Biotech is a developer of host-directed drugs as broad-spectrum treatments for chronic and severe infectious diseases. The company utilizes host-directed therapy strategies to interfere with host cell factors that are required by a pathogen for replication or persistence. The company engages in the discovery and development of new anti-infective drugs via immunomodulation.

MediQuo is a health-focused application that facilitates communication between patients and healthcare professionals, effectively serving as a "hospital in your pocket." The app addresses the high volume of unnecessary medical visits by enabling remote consultations through chat, video, and audio communication. MediQuo is compliant with GDPR regulations, ensuring the privacy and security of patient information while allowing healthcare providers to manage their time efficiently. The platform supports the exchange of medical files, including images and reports, enhancing diagnostic capabilities. With features for scheduling appointments and immediate 24/7 medical responses, MediQuo has garnered significant traction, achieving over 1 million consultations and 600,000 downloads. It maintains a high user satisfaction rating of 4.6 on Google Play, positioning itself among the leading health apps in Spain and Latin America.

Loop Dx is developing point-of-care diagnostics for faster detection of sepsis to reduce sepsis mortality, patient side effects, and antibiotic resistance due to unnecessary provided antibiotics. We want to facilitate healthcare providers the tools they need for faster sepsis identification saving lives and optimizing sepsis management.

Exheus tells everything that you need to know to take maximum care of yourself and avoid risks to your health, exheus is much more than a DNA test that only indicates which genes you have.

Oncostellae SL, founded in 2013 and based in Ourense, Spain, specializes in the development of small molecule drugs aimed at treating cancer. The company was established by a group of researchers with expertise in chemistry, biochemistry, and pharmacology, all of whom have experience in advancing clinical drug candidates through to phase II trials. Oncostellae's strategy focuses on creating pharmaceutical research programs that target validated cancer mechanisms, such as nuclear receptors and kinases. By maintaining a streamlined internal team that emphasizes project management, medicinal chemistry, and in vitro pharmacology, the company optimizes its operations. Other aspects of the research and development process, including in vivo pharmacology, toxicology, and clinical trials, are outsourced to specialized providers. Oncostellae aims to license its clinical drug candidates, including associated intellectual property and comprehensive data packages, to established pharmaceutical or biotechnology companies.

Inrobics is a company focused on enhancing rehabilitation through the integration of artificial intelligence and social robots. It offers a cloud-based platform that supports individuals with functional and neurological limitations, facilitating personalized treatment both in rehabilitation centers and at home. By developing robotics that promote interaction between patients and healthcare professionals, Inrobics aims to improve the quality of rehabilitation treatments. Their technology addresses various challenges faced by clients, including those stemming from brain damage and neurodevelopmental disorders, thereby providing essential support, well-being, and educational resources to enhance the rehabilitation experience.

Mowoot is a company that specializes in developing wearable medical devices aimed at improving the quality of life for individuals suffering from chronic constipation. Founded in 2014 and based in Barcelona, Spain, Mowoot offers a non-pharmacological and non-invasive solution that simulates a manual abdominal massage performed by healthcare professionals. Utilizing advanced pneumatic technology, its device provides automatic colon-specific massages to stimulate intestinal transit, thereby helping to treat and prevent chronic slow transit constipation without the need for colon cleansing supplements, enemas, or laxatives. Mowoot emerged from the MOEBIO dHEALTH program, drawing inspiration from concepts in design and business innovation.

Kintsugi Therapeutics is a preclinical biopharmaceutical company focused on developing innovative therapies for liver conditions, particularly Non-Alcoholic Steatohepatitis (NASH). The company specializes in creating endoplasmic reticulum (ER) stress inhibitors aimed at addressing liver disease and related pathologies. By targeting the regulation of ER stress, Kintsugi Therapeutics seeks to provide effective treatment options that can enhance patient outcomes and improve quality of life for individuals suffering from these conditions.

FrontWave Imaging is a developer of advanced medical imaging technology specializing in 3D ultrasound for breast cancer diagnosis. The company creates software that leverages supercomputing to enhance the quality of ultrasound images, thereby improving diagnostic accuracy. Its system facilitates a comprehensive workflow, including data transfer to the cloud, image reconstruction, and visualization through an intuitive user interface. This innovative approach allows healthcare professionals to monitor breast tumors effectively while minimizing patient exposure to harmful ionizing radiation. FrontWave Imaging aims to transform the medical diagnosis landscape for breast cancer by providing enhanced imaging capabilities and supporting better patient outcomes.

Corify Care SL is a medical technology company based in Madrid, Spain, focused on advancing the treatment of cardiac arrhythmias, particularly atrial fibrillation. Founded in 2019, the company has developed ACORYS, a non-invasive electrocardiographic imaging device that allows healthcare professionals to visualize the electrical activity of the heart without the need for invasive catheters or complex imaging techniques like MRI or CT scans. This innovative device addresses the limitations of existing solutions by providing real-time mapping of cardiac arrhythmias, which can significantly enhance the clinical management of atrial fibrillation. Corify Care's technology aims to improve treatment outcomes for millions of patients in Europe, enabling effective diagnosis and personalized care during routine cardiology visits.

Aortyx is a pioneering company founded by researchers from the IQS School of Engineering and the Hospital Clínic de Barcelona, dedicated to developing innovative endovascular devices for the treatment of vascular diseases. The company specializes in technology that promotes tissue regeneration by closely mimicking the biomechanical environment of the aorta. Its devices are designed to create a favorable environment for cell migration and proliferation, utilizing a bioresorbable platform that closely replicates the natural dynamics of the aorta. This approach aims to enhance the effectiveness of treatments for aortic diseases, providing healthcare professionals with advanced solutions for managing these conditions.

Aortyx is a pioneering company founded by researchers from the IQS School of Engineering and the Hospital Clínic de Barcelona, dedicated to developing innovative endovascular devices for the treatment of vascular diseases. The company specializes in technology that promotes tissue regeneration by closely mimicking the biomechanical environment of the aorta. Its devices are designed to create a favorable environment for cell migration and proliferation, utilizing a bioresorbable platform that closely replicates the natural dynamics of the aorta. This approach aims to enhance the effectiveness of treatments for aortic diseases, providing healthcare professionals with advanced solutions for managing these conditions.

Ekuore is a technology company that designs, develops, and markets medical devices that connect health to new mobile technologies. The company is driven by an aim to continue developing mHealth devices that revolutionize the sanitary teleassistance field, which allows patients to be controlled and monitored in a quick and easy way and at a low cost. Ekuore was founded in 2012 and is headquartered in Valencia, Spain.

Aortyx is a pioneering company founded by researchers from the IQS School of Engineering and the Hospital Clínic de Barcelona, dedicated to developing innovative endovascular devices for the treatment of vascular diseases. The company specializes in technology that promotes tissue regeneration by closely mimicking the biomechanical environment of the aorta. Its devices are designed to create a favorable environment for cell migration and proliferation, utilizing a bioresorbable platform that closely replicates the natural dynamics of the aorta. This approach aims to enhance the effectiveness of treatments for aortic diseases, providing healthcare professionals with advanced solutions for managing these conditions.

QMENTA is a software platform focused on imaging-based clinical studies, primarily aimed at enhancing the diagnosis and treatment of brain diseases. The company offers a cloud-based data management engine that integrates patented, AI-powered analytical algorithms alongside a marketplace of partnered algorithms. This platform allows healthcare professionals to compliantly collect, process, and analyze large-scale brain images and associated data efficiently. QMENTA's solutions encompass data management systems, clinical trials, neuroimaging disease packages, and neuro-data services, thereby facilitating improved medical imaging management and supporting clinical care and neuro research.

Ability Pharmaceuticals is a drug discovery and development company based in Barcelona, Spain. It develops human therapeutics targeting cell membranes to treat cancer and other indications with unmet medical needs. Ability Pharmaceuticals is focused on developing new drugs for the treatment of lung cancer and pancreatic cancer. The company develops Lipid Analogue Therapeutics, a new drug class that modifies the composition of the cell membrane and displays a capacity to influence the local organization of lipid structures in the cell membrane, inducing the formation of non-lamellar phase structures. Its development pipeline includes ABTL0812 product in preclinical development; and ABTL1014, a drug candidate in preclinical characterization.

Laminar Pharma is an innovative biopharmaceutical company dedicated to the discovery, rational design, and early clinical development of a new generation of medicines through a unique therapeutic approach known as Membrane Lipid Therapy (MLT). The company specializes in developing MLT-based drugs, as well as nutraceuticals and cosmetic products, all aimed at enhancing treatment options for physicians by targeting membrane lipids. By leveraging this novel strategy, Laminar Pharma seeks to advance healthcare solutions and improve patient outcomes with its cutting-edge therapeutic offerings.

Tractivus is a biotechnology company focused on addressing the challenges associated with biomedical devices by developing innovative implantable medical solutions. Originating as spin-offs from IQS and IDIBELL, Tractivus specializes in creating products that prevent bacterial colonization, thereby enhancing patient safety and device longevity. Their flagship technology, known as phobostech, employs advanced thin nanocoatings to impart bacteria-resistant properties to various medical devices, including catheters and tracheal stents. This patented approach not only extends the lifespan of the devices but also reduces associated healthcare costs and minimizes post-implantation complications, all while ensuring patient well-being.

Arrhythmia Algorithm S.L. (https://rithmi.com) is a privately held company with the mission to support people to take care of their heart and prevent health problems as the stroke. Their aim is to revolutionize the way Auricular fibrillation is diagnosed through a comfortable, compliant and innovative method. After successfully piloting the prototype version of RITHMI technology, the team can confirm the capability of its breakthrough product to open new markets in Europe with the potential for rapid growth. Rithmi is a pioneer in arrhythmia detection technologies and the leading company in Computational Predictive Care™.

RheoDx is a developer of a diagnostic medical device focused on enhancing the quality of life for hematology patients. The company's innovative technology measures the behavior of blood in motion, utilizing a sample as small as a drop to detect subtle changes in the rheological properties of red blood cells. These changes can indicate abnormalities in cell morphology or rigidity, which are linked to various diseases, including blood coagulation disorders, malignant homeopathies, malaria, and hereditary anemias. The device's compact size and user-friendly design enable point-of-care testing and home use, empowering patients to monitor their conditions conveniently and affordably.

DERMA INNOVATE, S.L. is a Biotechnology Company, created and owned by Cannan research & Investment, focused on obtaining a series of advanced compounds in the area of skin and hair regeneration.

Fesia Technology specializes in the development of advanced medical devices utilizing functional electrical stimulation for rehabilitation therapy, particularly for individuals affected by injuries and neuromuscular diseases. The company has created an innovative system featuring a matrix arrangement of electrodes, which enhances the effectiveness of functional stimulation. Its flagship product, Fesia Walk, is designed specifically for patients with foot drop and represents the first device in this new generation of rehabilitation technology. Fesia is committed to improving the quality of life for patients and equipping healthcare professionals with cutting-edge tools that facilitate rehabilitation, especially for those recovering from central nervous system injuries such as strokes.

Ability Pharmaceuticals is a drug discovery and development company based in Barcelona, Spain. It develops human therapeutics targeting cell membranes to treat cancer and other indications with unmet medical needs. Ability Pharmaceuticals is focused on developing new drugs for the treatment of lung cancer and pancreatic cancer. The company develops Lipid Analogue Therapeutics, a new drug class that modifies the composition of the cell membrane and displays a capacity to influence the local organization of lipid structures in the cell membrane, inducing the formation of non-lamellar phase structures. Its development pipeline includes ABTL0812 product in preclinical development; and ABTL1014, a drug candidate in preclinical characterization.

Arcis Biotechnology Limited specializes in the development and commercialization of nucleic acid sample preparation solutions. The company offers a range of ready-to-use kits, including the Arcis Sample Prep Kit, which facilitates the extraction of nucleic acids from diverse sample types such as whole blood, saliva, and various biological materials. Arcis’s DNA products enable rapid processing, allowing users to obtain genetic material in under three minutes without the need for laboratory equipment, using minimal sample volumes. Their technology supports applications in point-of-care diagnostics, veterinary research, and forensic analysis. Additionally, Arcis provides technical support services and distributes its products across several countries, including the United Kingdom, Ireland, and India. Founded in 2013 and based in Warrington, United Kingdom, the company was previously known as Arcis Molecular Limited before rebranding in 2018.

Adan Medical Innovation, S.L. is a biotechnology company based in Barcelona, Spain, specializing in the development of medical devices that enhance the management of anaphylaxis. Founded in 2014, the company focuses on improving the quality of life for patients experiencing severe allergic reactions that require epinephrine. Its flagship product, AnAPPhylaxis, is a smart case for epinephrine auto-injectors that connects to a mobile application, providing users with real-time information about the condition of the medication. The device also features alerts for users who forget their auto-injectors and activates an emergency action plan during an anaphylactic event, offering step-by-step instructions for drug administration and notifying predefined contacts with the user's location. Additionally, Adan Medical Innovation is developing WE SAVE, a smart box designed for public spaces to increase accessibility to epinephrine auto-injectors in emergencies.

Cebiotex specializes in manufacturing technology and contract research focused on drug delivery using electrospun nanofiber technology. The company has developed and characterized preclinical nonwoven nanofiber membranes, both in vitro and in vivo, aimed at the controlled release of active agents for the local treatment of unresectable tumors. This innovative approach enables medical professionals to effectively target and manage difficult-to-treat cancer cases, providing a potential advancement in cancer treatment methodologies.

Davalor Salud is a company focused on enhancing functional visual health through innovative technology. It develops and commercializes both hardware and software designed for the exploration and diagnosis of visual function. The company offers accessible services that autonomously measure vision and provide visual training using advanced 3D video game technology. By specializing in the diagnosis and therapy of functional visual health issues, Davalor Salud aims to improve the quality of life for its users, making effective visual health services more widely available to the public.

MJN improves the quality of life of people suffering from epilepsy thanks to our wearable ear piece that performs an EEG of the patient. By applying AI algorithms, MJN-SERAS is able to interpret the brain signal, record epileptic seizures, objectively improve the medical monitoring and permanently assess the risk of suffering an epilepsy seizure

Biohope is focused on creating diagnostic and therapeutic solutions specifically for organ transplantation. The company has developed a system aimed at providing immunological clinical management for kidney transplant patients. By analyzing a patient's blood sample, Biohope's system allows for the customization of treatment with immunosuppressive drugs. This tailored approach not only aids in the prevention of organ rejection but also extends its utility to the treatment of autoimmune diseases such as arthritis. Through its innovative technology, Biohope seeks to enhance patient outcomes in the field of transplantation and immunology.

Vytrus Biotech SL is a biotechnology company based in Barcelona, Spain, that specializes in the development, production, and commercialization of active ingredients derived from plant stem cells. Founded in 2009 as a spin-off from the University of Barcelona, the company leverages over 30 years of research in plant biotechnology to create high-value natural active ingredients primarily for the cosmetics and pharmaceutical industries. Its product offerings include a range of cosmetic solutions such as cell factor-rich plasma and phyto-peptidic fractions, as well as dermatologic and customized products. In 2016, the company changed its name from Phyture Biotech SL to Vytrus Biotech SL, reflecting its focus on innovative, plant-based active ingredients.

Absynth Biologics Limited is a biotechnology company focused on discovering and developing vaccines and therapeutic antibodies aimed at preventing and treating bacterial infections. Founded in 2007 and based in Alderley Edge, United Kingdom, the company targets significant pathogens, including Staphylococcus aureus, Clostridium difficile, and Streptococcus pyogenes. Utilizing a platform that identifies novel protein antigen targets, Absynth Biologics employs a dual-action mechanism that combines direct antibacterial activity through antibody-mediated effects and the engagement of immune effector functions to eliminate bacteria. By characterizing specific proteins from these bacteria as immunological targets, the company aims to enhance patient immunity and address serious health threats associated with bacterial infections.

Ducentis BioTherapeutics Limited is a pre-clinical stage company based in Witney, United Kingdom, focused on developing innovative therapies for inflammation and autoimmune diseases. Established in 2014, the company specializes in modifying a naturally occurring protein that plays a crucial role in immunoregulation. Ducentis targets the CD200/CD200R axis, which provides a deactivating signal to activated immune cells in both the innate and adaptive immune systems. The company's research aims to address various therapeutic needs, including transplant rejection and a range of autoimmune and inflammatory conditions affecting organs such as the lungs, liver, kidneys, eyes, bones, and cartilage.

TBIOM biotechnological startup that aims to develop sustainable medical products and solutions to help large sectors of the population. TBIOM is working on the development of different electronic mhealth devices such as the control system for chronic alcoholism ETHAXIP (intra-oral device) or the DALVC system for performing continuous bladder washes in hospital centers. This last device is being developed jointly with Vecmedical and Vall d'Hebrón Hospital . In addition, TBIOM has developed and patented a new CPAP device for sleep apnea, portable, autonomous and mHealth , which also manages and encourages the health and care of people with this respiratory difficulty called Airmony.

AROMICS is a biotech company committed to the discovery and development of novel drugs and diagnostic methods to target relevant human diseases and improve patient’s quality of life. They believe that OMIC technologies represent an important first step towards gaining biological insights into: How drugs work, giving them added value, reducing attrition rates and advancing through the clinic. Determining clinically predictive molecular endpoints that help physicians manage the disease, drive prescriptions and monitor drug response.

Bionure is a late-preclinical company focused at developing First-in-Class SGK agonists for the treatment of rare ophthalmology diseases.

Cebiotex specializes in manufacturing technology and contract research focused on drug delivery using electrospun nanofiber technology. The company has developed and characterized preclinical nonwoven nanofiber membranes, both in vitro and in vivo, aimed at the controlled release of active agents for the local treatment of unresectable tumors. This innovative approach enables medical professionals to effectively target and manage difficult-to-treat cancer cases, providing a potential advancement in cancer treatment methodologies.

The Pump it Nanotech S.L is a Start Up born from the Pump it project. This project was a response to the challenge presented by SENER, regarding the troublesome behaviour of bubbles in microfluidic devices in microgravity, during the 5th Ideas Generation Program: Aeroespacial Technologies from UAB (PRUAB).

Bioprognos is a spin-off of the Hospital Clínic of Barcelona that aims to improve clinical outcomes and quality of life for cancer, by developing innovative, non-invasive, accurate, and cost-effective diagnostics solutions.

Cebiotex specializes in manufacturing technology and contract research focused on drug delivery using electrospun nanofiber technology. The company has developed and characterized preclinical nonwoven nanofiber membranes, both in vitro and in vivo, aimed at the controlled release of active agents for the local treatment of unresectable tumors. This innovative approach enables medical professionals to effectively target and manage difficult-to-treat cancer cases, providing a potential advancement in cancer treatment methodologies.

Braingaze is a company focused on addressing cognitive disorders through innovative technology. It has developed a patented neuro-biomarker that utilizes small involuntary eye movements, triggered by functional games, to analyze cognitive function. The resulting data is processed using advanced algorithms trained through Deep Learning, leveraging real patient and control cases. Braingaze's tools are designed to detect and diagnose pre-symptomatic stages of Alzheimer's disease and the common childhood cognitive disorder ADHD. These tools are already available on the market and carry a CE Mark as medical devices. In addition to diagnostic capabilities, Braingaze is also advancing digital therapy solutions that have demonstrated the potential to reduce symptoms by more than 50%.

Capital Cell is a European equity crowdfunding platform based in Barcelona, Spain, that specializes in biotechnology and life sciences projects. Founded in 2014, the company serves as a meeting point for entrepreneurs and private investors, including venture capitalists and business angels, to facilitate funding for innovative medical science initiatives. By leveraging the power of the crowd, Capital Cell enables researchers and companies in the biotech sector to access a diverse pool of investment, thereby fostering the growth and development of cutting-edge solutions in healthcare.

QMENTA is a software platform focused on imaging-based clinical studies, primarily aimed at enhancing the diagnosis and treatment of brain diseases. The company offers a cloud-based data management engine that integrates patented, AI-powered analytical algorithms alongside a marketplace of partnered algorithms. This platform allows healthcare professionals to compliantly collect, process, and analyze large-scale brain images and associated data efficiently. QMENTA's solutions encompass data management systems, clinical trials, neuroimaging disease packages, and neuro-data services, thereby facilitating improved medical imaging management and supporting clinical care and neuro research.

ZeClinics is a biotechnology start-up that specializes in drug and pharmaceutical development using zebrafish as a model organism. The company provides an outsourcing solution for safety and efficacy screenings of novel chemical compounds. Utilizing its advanced platform, ZeClinics conducts toxicology screenings by tracking toxicity data and preserving embryos of marine species. The company employs zebrafish larvae to evaluate the toxicity of drugs and related protein molecules, allowing biotechnologists to assess drug safety and recommend appropriate dosages. Through its innovative approach, ZeClinics aims to enhance the drug development process by offering reliable and efficient testing solutions.

Developing a genetic test to help reduce the risk of hospital infections.